drugset / Trial / NCT02914600
Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
Non-randomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in Crohn's disease (CD).
Timeline
- Start
- 2017-03-17
- Primary completion
- 2023-08-01
- Completion
- 2023-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Filgotinib | Small molecule | 100 mg | Oral |
| Subject | Filgotinib | Small molecule | 200 mg | Oral |